Shareholders Approve 1-for-10 to 1-for-30 Reverse Stock Split
VRAX sits 74% above its 52-week low of $0.1.
Summary
Virax Biolabs shareholders approved a reverse stock split, ranging from 1-for-10 to 1-for-30, along with amended articles of association to reflect the new share capital structure.
Key Events · Corporate Governance and Compliance · VRAX
-
Reverse Stock Split Approved
Shareholders approved a share consolidation (reverse stock split) on a basis of one (1) share for every ten (10) to thirty (30) outstanding ordinary shares.
-
Amended Articles of Association Approved
The form of the fourth amended and restated memorandum and articles of association was approved to reflect the revised authorized share capital, effective with the share consolidation.
-
Extraordinary General Meeting Details
The Extraordinary General Meeting was initially adjourned due to a lack of quorum (3.6% present) but reconvened on June 12, 2026, where the shareholders present (3.65%) constituted a quorum as per company articles.
Analysis · VRAX · Life Sciences
Shareholders have approved a reverse stock split, a critical move for a company trading at a low share price. This action is typically undertaken to increase the per-share price to meet exchange listing requirements and potentially attract a broader investor base. The wide range of the split (1-for-10 to 1-for-30) gives the board flexibility in determining the final ratio.
At the time of this filing, VRAX was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.10 to $1.14. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.